HLA-DRA and sarcopenia: Interestingly, the impact direction of increased HP and down‐regulated HLA‐DRA is the same as that on sarcopenia, implying that drug targets on HP and HLA‐DRA for sarcopenia may also be beneficial for these diseases, including sarcopenia and dyslipidaemia diseases (Figure S3).